Bristol-Myers Squibb Co. will pay up to $1.3 billion, including a $150 million up-front payment, for an exclusive right to acquire Promedior Inc. and worldwide rights to the company's lead asset, a recombinant form of human pentraxin-2 protein, called PRM-151, that is in development for the treatment of IPF and myelofibrosis.